Repository logo
 

Cell surface IL-1α trafficking is specifically inhibited by interferon-γ, and associates with the membrane via IL-1R2 and GPI anchors.

Accepted version
Peer-reviewed

Type

Article

Change log

Authors

Chan, Julie NE 
Humphry, Melanie 
Kitt, Lauren 
Krzyzanska, Dominika 
Filbey, Kara J 

Abstract

IL-1 is a powerful cytokine that drives inflammation and modulates adaptive immunity. Both IL-1α and IL-1β are translated as proforms that require cleavage for full cytokine activity and release, while IL-1α is reported to occur as an alternative plasma membrane-associated form on many cell types. However, the existence of cell surface IL-1α (csIL-1α) is contested, how IL-1α tethers to the membrane is unknown, and signaling pathways controlling trafficking are not specified. Using a robust and fully validated system, we show that macrophages present bona fide csIL-1α after ligation of TLRs. Pro-IL-1α tethers to the plasma membrane in part through IL-1R2 or via association with a glycosylphosphatidylinositol-anchored protein, and can be cleaved, activated, and released by proteases. csIL-1α requires de novo protein synthesis and its trafficking to the plasma membrane is exquisitely sensitive to inhibition by IFN-γ, independent of expression level. We also reveal how prior csIL-1α detection could occur through inadvertent cell permeabilisation, and that senescent cells do not drive the senescent-associated secretory phenotype via csIL-1α, but rather via soluble IL-1α. We believe these data are important for determining the local or systemic context in which IL-1α can contribute to disease and/or physiological processes.

Description

Keywords

IL-1, Inflammation, Innate immunity, Interferon, Macrophage, Animals, Cell Membrane, Glycosylphosphatidylinositols, Humans, Inflammation, Interferon-gamma, Interleukin-1alpha, Macrophages, Male, Mice, Mice, Inbred C57BL, Protein Binding, Protein Transport, Receptors, Interleukin-1 Type II

Journal Title

Eur J Immunol

Conference Name

Journal ISSN

0014-2980
1521-4141

Volume Title

50

Publisher

Wiley

Rights

All rights reserved
Sponsorship
British Heart Foundation (None)
British Heart Foundation (None)
British Heart Foundation (RG/16/8/32388)
British Heart Foundation (FS/18/19/33371)
British Heart Foundation (None)
British Heart Foundation (FS/18/19/33371)
British Heart Foundation (None)
British Heart Foundation (None)
British Heart Foundation (CH/2000003/12800)
British Heart Foundation (PG/16/11/32021)
British Heart Foundation (RG/20/2/34763)
British Heart Foundation (PG/16/24/32090)
British Heart Foundation (FS/20/19/34976)
Work was funded by British Heart Foundation Grants FS/13/3/30038, FS/18/19/33371 and RG/16/8/32388 to MCHC, the BHF Cambridge CRE RE/13/6/30180, and the Cambridge NIHR Biomedical Research Centre